Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
作者： Claus‐Henning Köhne , Heinz‐Josef Lenz
DOI: 10.1634/THEONCOLOGIST.2008-0202
关键词:
摘要: The introduction of novel agents targeted to specific molecular features cancer cells promises more options and marked improvements in efficacy for treatment colon cancer. This overview clinical studies describes the effects administering bevacizumab, cetuximab, panitumumab, also known as monoclonal antibodies, treat metastatic colorectal (mCRC) patients. All three have been approved use by U.S. Food Drug Administration European Agency Evaluation Medicinal Products. Bevacizumab has shown extend survival when used combination with irinotecan 5-fluorouracil-based chemotherapy, addition cetuximab chemotherapy overcomes resistance. Cetuximab panitumumab are both efficacious among refractory mCRC patients wild-type KRAS tumors. Other agents, example, tyrosine kinase inhibitors erlotinib, gefitinib, sunitinib, vatalanib (PTK787/ZK 222584), currently various stages development.
alphamedpress.org 参考文章(65)
Corazon D. Bucana, Yasuhiko Kitadai, Karen R. Cleary, Lee M. Ellis, Yutaka Takahashi, Expression of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with Vascularity, Metastasis, and Proliferation of Human Colon Cancer Cancer Research. ,vol. 55, pp. 3964- 3968 ,(1995)
J Tol, M Koopman, NF Antonini, H Sinnige, FAA Valster, JJ Braun, AJ ten Tije, L Mol, JHJM van Krieken, C Punt, Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) Journal of Clinical Oncology. ,vol. 26, ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.LBA4011
M. Peeters, G. Wilson, M. Ducreux, A. Cervantes, T. André, Y. Hotko, F. Lordick, S. Collins, M. Shing, T. J. Price, Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results Journal of Clinical Oncology. ,vol. 26, pp. 4064- 4064 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4064
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Journal of Clinical Oncology. ,vol. 22, pp. 3766- 3775 ,(2004) , 10.1200/JCO.2004.03.104
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
A de Gramont, J F Bosset, C Milan, P Rougier, O Bouché, P L Etienne, F Morvan, C Louvet, T Guillot, E François, L Bedenne, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology. ,vol. 15, pp. 808- 815 ,(1997) , 10.1200/JCO.1997.15.2.808
Eric Van Cutsem, Karen Geboes, The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer Best Practice & Research in Clinical Gastroenterology. ,vol. 21, pp. 1089- 1108 ,(2007) , 10.1016/J.BPG.2007.10.020
K Jin Kim, Bing Li, Jane Winer, Mark Armanini, Nancy Gillett, Heidi S Phillips, Napoleone Ferrara, None, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature. ,vol. 362, pp. 841- 844 ,(1993) , 10.1038/362841A0
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter, None, The biology of VEGF and its receptors. Nature Medicine. ,vol. 9, pp. 669- 676 ,(2003) , 10.1038/NM0603-669
Irena Porębska, Antonina Harłozińska, Tomasz Bojarowski, Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biology. ,vol. 21, pp. 105- 115 ,(2000) , 10.1159/000030116